利索-全球专利检索

  1. 登录
  2. 注册
发明授权
US07531629B2 Tumor associated antigen peptides and use of same as anti-tumor vaccines 失效
肿瘤相关抗原肽及其与抗肿瘤疫苗的使用

Tumor associated antigen peptides and use of same as anti-tumor vaccines
摘要：
The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.
摘要（中）：

本发明涉及肿瘤相关抗原（TAA）肽及其使用方法，其编码相同的多核苷酸和与抗肿瘤疫苗相同的细胞。 更具体地说，本发明涉及衍生自Uroplatinin Ia，Ib，II和III，前列腺特异性抗原（PSA），前列腺酸性磷酸酶（PAP）和前列腺特异性膜抗原（PSMA），BA-46（Lactadherin ），粘蛋白（MUC-1）和细胞因子来源的生长因子（CRIPTO-1），以及其与抗肿瘤疫苗的用途预防或治愈膀胱，前列腺，乳腺癌或其他癌症，特别是癌症。 最特别地，本发明涉及可由HLA-A2分子呈递给免疫系统的肿瘤相关抗原肽。

公开/授权文献
信息查询
Espacenet
0/0